mtraore – Page 20

22/07/2015 : Theradiag signs collaboration agreements with Unicancer and Bordeaux University Hospital to advance microRNA project in rectal cancer

Post author:mtraore
Post published:22 July 2015
Post category:Press Releases

Theradiag reaches new milestone in the development of two new theranostics tests in rectal cancerTheradiag secures access to multicentric patient cohorts with two leading cancer research partnersCroissy-Beaubourg and Montpellier, July 22, 2015 – Theradiag (ISIN:…

17/07/2015 : New study shows predictive role of theranostics in Inflammatory Bowel Disease

Post author:mtraore
Post published:17 July 2015
Post category:Press Releases

Further validation of routine biotherapy monitoring in IBD patientsUndetectable anti-TNF drug levels in IBD patients with long-term remission predicts relapse-free survival after drug withdrawal Croissy-Beaubourg and Montpellier, June 17, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER),…

26/05/2015 : THERADIAG RECEIVES FROST & SULLIVAN 2015 EUROPEAN THERANOSTICS PRODUCT LEADERSHIP AWARD

Post author:mtraore
Post published:26 May 2015
Post category:Press Releases

Croissy-Beaubourg and Montpellier, May 26, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that is has been awarded the Frost & Sullivan 2015 European Theranostics Product…

22/07/2015 : Theradiag signs collaboration agreements with Unicancer and Bordeaux University Hospital to advance microRNA project in rectal cancer

17/07/2015 : New study shows predictive role of theranostics in Inflammatory Bowel Disease

26/05/2015 : THERADIAG RECEIVES FROST & SULLIVAN 2015 EUROPEAN THERANOSTICS PRODUCT LEADERSHIP AWARD

14th International Congress on Autoimmunity

GEAI Colloquium

Annual SALF Congress